Bachem Holding AG
BANB
Rank in Stocks
#2516
Bachem Holding AG serves pharmaceutical and biotechnology companies globally,... Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Share Price
$100.60
Market Cap
$7.54B
Change (1 day)
-1.49%
Change (1 year)
49.53%
Country
CH
Trade Bachem Holding AG (BANB)
Category
Healthcare
Revenue for Bachem Holding AG (BANB)
Revenue in Oct 2026 TTM: 0
According to Bachem Holding AG latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Bachem Holding AG from 2002 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2025 | $875.88M | 30.72% |
| 2024 | $670.05M | -2.39% |
| 2023 | $686.47M | 19.36% |
| 2022 | $575.15M | 4.20% |
| 2021 | $551.97M | 23.34% |
| 2020 | $447.51M | 38.00% |
| 2019 | $324.29M | 12.93% |
| 2018 | $287.17M | 6.98% |
| 2017 | $268.42M | 15.53% |
| 2016 | $232.34M | 11.33% |
| 2015 | $208.69M | 12.70% |
| 2014 | $185.17M | -3.20% |
| 2013 | $191.29M | 11.30% |
| 2012 | $171.87M | 10.72% |
| 2011 | $155.22M | -5.12% |
| 2010 | $163.59M | -7.04% |
| 2009 | $175.99M | -3.60% |
| 2008 | $182.56M | 4.04% |
| 2007 | $175.47M | 24.55% |
| 2006 | $140.88M | 20.66% |
| 2005 | $116.75M | -10.21% |
| 2004 | $130.03M | 11.21% |
| 2003 | $116.92M | 7.90% |
| 2002 | $108.36M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
